DexCom, Inc. , a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.
Dexcom stock last closed at $118.89, up 0.81% from the previous day, and has increased 0.83% in one year. It has overperformed other stocks in the Medical Devices industry by 0.19 percentage points. Dexcom stock is currently +59.05% from its 52-week low of $74.75, and -14.8% from its 52-week high of $139.55.
At the moment, there are 386.37M DXCM shares outstanding. The market capitalization of DXCM is $45.94B. In the past 24 hours, 2.39M DXCM shares were traded.
You will need an online brokerage account to access the NASDAQ market and buy DXCM stock.
We believe that eToro is the best brokerage. eToro gives you:
Get $10 towards your purchase of shares by creating an account with eToro today.Open eToro Account
Now that you've selected your brokerage, it's time to fill out some personal information so you are able to invest in DXCM stock today.
Now that you have created your account on stock apps to use, your next step is to transfer the money for your investment:
Check out the video below to see the process of transferring funds into your new brokerage account.
Once you have selected the best place to buy Dexcom stock, it's crucial to evaluate their stock prior to buying, so you truly wrap your head around the risk as well as the upside.
WallStreetZen was designed to help everyday investors do more accurate fundamental analysis in less time.
You can see all of the due diligence checks on DXCM's stock page.
You can use a variety of different financial metrics, analyses, models, and charts to gauge DXCM's intrinsic value.
Using relative valuations metrics:
You can do additional valuation analysis on DXCM's stock here.
Out of 12 Wall Street analysts who give recommendations on DXCM, the consensus analyst rating on Dexcom is a Strong Buy
Please note that analyst forecasts are not recommendations, nor are they investment advice.
Danielle Antalffy, a bottom 3% analyst from UBS maintains DXCM with a strong buy rating and lowers their DXCM price target from $175.00 to $138.00, on Sep 6, 2023.
Jeff Johnson, a top 14% analyst from Baird maintains DXCM with a buy rating and lowers their DXCM price target from $153.00 to $130.00, on Aug 21, 2023.
Matt Miksic, a bottom 5% analyst from Barclays maintains DXCM with a hold rating and raises their DXCM price target from $115.00 to $138.00, on Jul 31, 2023.
Matthew O'Brien, a bottom 5% analyst from Piper Sandler maintains DXCM with a strong buy rating and raises their DXCM price target from $150.00 to $160.00, on Jul 28, 2023.
Kyle Rose, a top 10% analyst from Canaccord Genuity maintains DXCM with a strong buy rating and raises their DXCM price target from $135.00 to $150.00, on Jul 28, 2023.
Canaccord Genuity's Kyle Rose raised their price target on Dexcom Inc (NASDAQ: DXCM) by 11.11% from $135.00 to $150.00 on 2023/07/28. The analyst maintained their Strong Buy rating on the stock.
The analyst said they raised their PT to reflect the "impressive" Q2 2023 results DexCom delivered on 2023/07/27.
The company posted a beat on revenue and earnings, together with another quarterly record for new patient adds, Rose reported.
In addition, management raised its FY 2023 revenue guidance to account for the company's "solid" 1H performance, the analyst said, "particularly the robust onboarding of basal-only T2 patients."
For Q2 2023, DexCom reported:
Management guided for FY 2023:
CEO Kevin Sayer commented, “In Q2, we advanced several key strategic initiatives and shared our latest vision for the future of Dexcom at our 2023 Investor Day.
“Given our strong start to the year and rapidly growing market opportunity, we are pleased to raise our 2023 revenue and margin guidance.”
You can dig deeper into what analysts are forecasting on the Dexcom stock forecast page.
Last year, DXCM earnings were $377.00M. During the past 5 year, DXCM's earnings have increased by 52.2% per year. This was faster than the Medical Devices industry average of 21.12%.
Last year, DXCM revenue was $3.40B. In the past 5 year, DXCM's revenue has grown by 30.05% per year. This was faster than the Medical Devices industry average of 12.72%.
You can analyze DXCM's earnings and revenue performance here.
Over the last year, executives and large shareholders at DXCM have sold more shares than they have bought.
Michael Jon Brown, EVP Chief Legal Officer of DXCM, was the latest DXCM insider to sell. They sold $135,043.74 worth of DXCM stock on Dec 1, 2023.
Research more about who owns DXCM shares here.
No, Dexcom doesn't provide an income stream by paying out dividends.
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other traders have to say.
You have two main options:
Hit the Open Trade button and eToro will execute your order.
If you want more info about investing in stocks on eToro, watch the how to video below:
Now that you own some DXCM shares, you'll want to stay up-to-date on your new investment.
Make a watchlist to get notified of important updates regarding your DXCM stock.
To reiterate, here are the 6 steps for buying Dexcom stock:
If you need a brokerage, eToro is our recommended venue.Get Started with eToro Today
If you want to monitor your investment in Dexcom, create a watchlist on WallStreetZen today.
How much does it cost to buy one Dexcom share?
Is now a good time to buy Dexcom stock?
What is the best way to buy Dexcom stock?